The chemical compound anle138b eases cognitive deficits and normalizes gene expression in a mouse model of Alzheimer’s disease and it seems to close harmful openings in the membrane of nerve cells as an international team of researchers including researchers of the MPI for Biophysical Chemistry found out. The scientists suggest that anle138b should be validated in clinical trials for its potential to treat Alzheimer’s and further neurodegenerative diseases.
In cooperation with colleagues in Göttingen and Munich, researchers at the German Center for Neurodegenerative Diseases have analyzed a novel substance that could serve as a prototype for the development of drugs to treat Alzheimer’s and other brain diseases. This substance ameliorated disease symptoms in mice and improved their cognition.
Lock pick or bunch of keys: what proteins and safecrackers have in common Novel NMR spectroscopic parameters allowed to determine not only the average structure of the protein ubiquitin but in addition the description of a faithful ensemble of the protein in solution. The ensemble reflected especially the previously inaccessible time window between 5 ns and 50 µs. The ensemble revealed the mechanism of protein protein recognition for this protein. If this was general new strategies for modulation of protein protein recognition would open up that could be used for more efficient drug development. (in German)more